

Global Ankylosing Spondylitis Treatment Market Report and Forecast 2023-2031

Market Report | 2023-04-11 | 147 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global Ankylosing Spondylitis Treatment Market Report and Forecast 2023-2031

Global Ankylosing Spondylitis Treatment Market Outlook

The ankylosing spondylitis treatment market size is being driven by the increasing prevalence of the condition and the growing investment in research and development activities. The market was estimated to be worth USD 4.64 billion in 2022. The market is anticipated to grow at a CAGR of 8.1% during the forecast period of 2023-2031 to reach USD 9.37 billion by 2031.

Ankylosing Spondylitis Treatment Market: Introduction

Ankylosing spondylitis is a type of arthritis that affects the joints of the spine. The disease causes inflammation in the joints and can lead to chronic pain, stiffness, and the eventual fusion of the spine. There is currently no cure for ankylosing spondylitis but there are various treatment options available in the market that aim to manage the symptoms of the disease. The report covers the market for ankylosing spondylitis treatment, including drugs and therapies, and provides a detailed analysis of the market size, growth, and trends.

Ankylosing Spondylitis Epidemiology

Ankylosing spondylitis is a chronic autoimmune disease that affects approximately 0.1% to 1% of the global population. The disease is more common in men than in women, with a male-to-female ratio of approximately 2:1. The disease typically begins in young adulthood and can progress over time, leading to chronic pain, stiffness, and the eventual fusion of the spine.

Ankylosing spondylitis is a chronic inflammatory disorder that affects the spine and sacroiliac joints. The exact cause of the disease is unknown but it is believed to be a combination of genetic and environmental factors. The disease is more common in men than women, and typically affects individuals in their late teens to early 30s.

The treatment options for ankylosing spondylitis are focused on reducing inflammation, managing pain and stiffness, and improving mobility. Nonsteroidal anti-inflammatory drugs (NSAIDs) and biologic agents are commonly used to manage the symptoms of the disease. Physical therapy, exercise, and other forms of rehabilitation are also important components of treatment.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Ankylosing Spondylitis Treatment Market Segmentations

The market can be categorised into drug type, indication type, treatment method, treatment channel, and major regions.

Market Breakup by Drug Type

- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
- Tumour Necrosis Factor (TNF) Inhibitors
- Interleukin (IL) Inhibitors
- Others

Market Breakup by Indication Type

- Medication
- Reactive Arthritis
- Psoriatic Arthritis
- IBD Associated Arthritis
- Juvenile Spondyloarthritis
- Undifferentiated Spondyloarthritis
- Others

Market Breakup by Treatment Method

- Physiotherapy and Exercise
- Painkillers
- Biological Treatments
- Corticosteroids
- Disease Modifying Anti Rheumatic Drugs (DMARDs)
- Surgery
- Others

Market Breakup by Treatment Channel

- Medication
- Public
- Private

Ankylosing Spondylitis Treatment Market Breakup by Region

- North America
 - ?□United States of America
 - ?□Canada
- Europe
 - ?□United Kingdom
 - ?□Germany
 - ?□France
 - ?□Italy
 - ?□Others
- Asia Pacific
 - ?□China
 - ?□Japan
 - ?□India
 - ?□ASEAN
 - ?□Australia
 - ?□Others
- Latin America
 - ?□Brazil

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- ? Argentina
- ? Mexico
- ? Others
- Middle East and Africa
- ? Saudi Arabia
- ? United Arab Emirates
- ? Nigeria
- ? South Africa
- ? Others

Ankylosing Spondylitis Treatment Market Scenario

The global ankylosing spondylitis treatment market is expected to grow at a significant rate during the forecast period of 2023-2031. The increasing prevalence of the disease, growing awareness, and advancements in medical technology are the key drivers of the market. North America dominates the market, followed by Europe and Asia Pacific. The leading players in the market are focusing on the development of new drugs and therapies and adopting various strategies to strengthen their position in the market.

North America dominates the ankylosing spondylitis treatment market, followed by Europe and Asia Pacific. The high prevalence of ankylosing spondylitis in North America, coupled with the favourable reimbursement policies, is driving the growth of the market in the region. Europe is also a significant market for ankylosing spondylitis treatment, with the presence of key players and increasing investment in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about the disease and the rising healthcare expenditure in the region.

Key Players in the Global Ankylosing Spondylitis Treatment Market

The report gives an in-depth analysis of the key players involved in the ankylosing spondylitis treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

- AbbVie Inc.
- Amgen Inc.
- Gilead Sciences
- Eli Lilly and Company
- Johnson & Johnson
- Novartis AG
- Pfizer Inc.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
- 2 Research Methodology
- 3 Executive Summary
- 4 Ankylosing Spondylitis (AS) Overview
 - 4.1 Guidelines and Stages

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.2 Pathophysiology
- 4.3 Screening and Diagnosis
- 4.4 Treatment Pathway
- 5 Patient Profile
 - 5.1 Patient Profile Overview
 - 5.2 Patient Psychology and Emotional Impact Factors
 - 5.3 Risk Assessment and Treatment Success Rate
- 6 Current Scenario Evaluation and Regulatory Framework
 - 6.1 Emerging Therapies and Clinical Trials
 - 6.2 Patent Landscape
 - 6.2.1 Patent Overview
 - 6.2.1.1 Patent Status and Expiry
 - 6.2.1.2 Timelines from Drug Development to Commercial Launch
 - 6.2.1.3 New Drug Application
 - 6.2.1.3.1 Documentation and Approval Process
 - 6.2.2 Cost of Treatment
 - 6.2.3 Regulatory Framework
 - 6.2.3.1 Regulatory Overview
 - 6.2.3.1.1 US FDA
 - 6.2.3.1.2 EU EMA
 - 6.2.3.1.3 INDIA CDSCO
 - 6.2.3.1.4 JAPAN PMDA
 - 6.2.3.1.5 Others
- 7 Challenges and Unmet Needs
 - 7.1 Treatment Pathway Challenges
 - 7.2 Compliance and Drop-Out Analysis
 - 7.3 Awareness and Prevention Gaps
- 8 Global Ankylosing Spondylitis Treatment Market
 - 8.1 Global Ankylosing Spondylitis Treatment Market Overview
 - 8.2 Global Ankylosing Spondylitis Treatment Market Analysis
 - 8.2.1 Market Overview
 - 8.2.1.1 Global Ankylosing Spondylitis Treatment Market Historical Value (2016-2022)
 - 8.2.1.2 Global Ankylosing Spondylitis Treatment Market Forecast Value (2023-2031)
 - 8.3 Global Ankylosing Spondylitis Treatment Market by Drug Type
 - 8.3.1 Market Overview
 - 8.3.1.1 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
 - 8.3.1.2 TNF Inhibitors
 - 8.3.1.3 Others
 - 8.4 Global Ankylosing Spondylitis Treatment Market by Indication Type
 - 8.4.1 Market Overview
 - 8.4.1.1 Reactive Arthritis
 - 8.4.1.2 Psoriatic Arthritis
 - 8.4.1.3 IBD Associated Arthritis
 - 8.4.1.4 Juvenile Spondyloarthritis
 - 8.4.1.5 Undifferentiated Spondyloarthritis
 - 8.4.1.6 Others
 - 8.5 Global Ankylosing Spondylitis Treatment Market by Treatment Method

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.5.1 Market Overview
 - 8.5.1.1 Physiotherapy and Exercise
 - 8.5.1.2 Painkillers
 - 8.5.1.3 Biological Treatments
 - 8.5.1.4 Corticosteroids
 - 8.5.1.5 Disease Modifying Anti Rheumatic Drugs (DMARDs)
 - 8.5.1.6 Surgery
 - 8.5.1.7 Others
- 8.6 Global Ankylosing Spondylitis Treatment Market by Treatment Channel
 - 8.6.1 Market Overview
 - 8.6.1.1 Public
 - 8.6.1.2 Private
- 8.7 Global Ankylosing Spondylitis Treatment Market by Region
 - 8.7.1 Market Overview
 - 8.7.1.1 North America
 - 8.7.1.2 Europe
 - 8.7.1.3 Asia Pacific
 - 8.7.1.4 Latin America
 - 8.7.1.5 Middle East and Africa
- 9 North America Ankylosing Spondylitis Treatment Market
 - 9.1 Market Share by Country
 - 9.2 United States of America
 - 9.2.1 Historical Trend (2016-2022)
 - 9.2.2 Forecast Trend (2023-2031)
 - 9.3 Canada
 - 9.3.1 Historical Trend (2016-2022)
 - 9.3.2 Forecast Trend (2023-2031)
- 10 Europe Ankylosing Spondylitis Treatment Market
 - 10.1 Market Share by Country
 - 10.2 United Kingdom
 - 10.2.1 Historical Trend (2016-2022)
 - 10.2.2 Forecast Trend (2023-2031)
 - 10.3 Germany
 - 10.3.1 Historical Trend (2016-2022)
 - 10.3.2 Forecast Trend (2023-2031)
 - 10.4 France
 - 10.4.1 Historical Trend (2016-2022)
 - 10.4.2 Forecast Trend (2023-2031)
 - 10.5 Italy
 - 10.5.1 Historical Trend (2016-2022)
 - 10.5.2 Forecast Trend (2023-2031)
 - 10.6 Others
- 11 Asia Pacific Ankylosing Spondylitis Treatment Market
 - 11.1 Market Share by Country
 - 11.2 China
 - 11.2.1 Historical Trend (2016-2022)
 - 11.2.2 Forecast Trend (2023-2031)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.3 Japan
 - 11.3.1 Historical Trend (2016-2022)
 - 11.3.2 Forecast Trend (2023-2031)
- 11.4 India
 - 11.4.1 Historical Trend (2016-2022)
 - 11.4.2 Forecast Trend (2023-2031)
- 11.5 ASEAN
 - 11.5.1 Historical Trend (2016-2022)
 - 11.5.2 Forecast Trend (2023-2031)
- 11.6 Australia
 - 11.6.1 Historical Trend (2016-2022)
 - 11.6.2 Forecast Trend (2023-2031)
- 11.7 Others
- 12 Latin America Ankylosing Spondylitis Treatment Market
 - 12.1 Market Share by Country
 - 12.2 Brazil
 - 12.2.1 Historical Trend (2016-2022)
 - 12.2.2 Forecast Trend (2023-2031)
 - 12.3 Argentina
 - 12.3.1 Historical Trend (2016-2022)
 - 12.3.2 Forecast Trend (2023-2031)
 - 12.4 Mexico
 - 12.4.1 Historical Trend (2016-2022)
 - 12.4.2 Forecast Trend (2023-2031)
 - 12.5 Others
- 13 Middle East and Africa Ankylosing Spondylitis Treatment Market
 - 13.1 Market Share by Country
 - 13.2 Saudi Arabia
 - 13.2.1 Historical Trend (2016-2022)
 - 13.2.2 Forecast Trend (2023-2031)
 - 13.3 United Arab Emirates
 - 13.3.1 Historical Trend (2016-2022)
 - 13.3.2 Forecast Trend (2023-2031)
 - 13.4 Nigeria
 - 13.4.1 Historical Trend (2016-2022)
 - 13.4.2 Forecast Trend (2023-2031)
 - 13.5 South Africa
 - 13.5.1 Historical Trend (2016-2022)
 - 13.5.2 Forecast Trend (2023-2031)
 - 13.6 Others
- 14 Global Ankylosing Spondylitis Treatment Market Dynamics
 - 14.1 Market Drivers and Constraints
 - 14.2 SWOT Analysis
 - 14.3 Porter's Five Forces Model
 - 14.4 Key Demand Indicators
 - 14.5 Key Price Indicators
 - 14.6 Industry Events, Initiatives & Trends

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.7 Value Chain Analysis
- 15 Supplier Landscape
 - 15.1 Abvie, Inc.
 - 15.1.1 Company Overview
 - 15.1.2 Product Portfolio
 - 15.1.3 Demographic Reach and Achievements
 - 15.1.4 Mergers and Acquisitions
 - 15.1.5 Certifications
 - 15.2 Amgen Inc.
 - 15.2.1 Company Overview
 - 15.2.2 Product Portfolio
 - 15.2.3 Demographic Reach and Achievements
 - 15.2.4 Mergers and Acquisitions
 - 15.2.5 Certifications
 - 15.3 Eli Lilly & Company
 - 15.3.1 Company Overview
 - 15.3.2 Product Portfolio
 - 15.3.3 Demographic Reach and Achievements
 - 15.3.4 Mergers and Acquisitions
 - 15.3.5 Certifications
 - 15.4 Gilead Sciences
 - 15.4.1 Company Overview
 - 15.4.2 Product Portfolio
 - 15.4.3 Demographic Reach and Achievements
 - 15.4.4 Mergers and Acquisitions
 - 15.4.5 Certifications
 - 15.5 Johnson & Johnson (Janssen)
 - 15.5.1 Company Overview
 - 15.5.2 Product Portfolio
 - 15.5.3 Demographic Reach and Achievements
 - 15.5.4 Mergers and Acquisitions
 - 15.5.5 Certifications
 - 15.6 Pfizer Inc.
 - 15.6.1 Company Overview
 - 15.6.2 Product Portfolio
 - 15.6.3 Demographic Reach and Achievements
 - 15.6.4 Mergers and Acquisitions
 - 15.6.5 Certifications
 - 15.7 Novartis AG
 - 15.7.1 Company Overview
 - 15.7.2 Product Portfolio
 - 15.7.3 Demographic Reach and Achievements
 - 15.7.4 Mergers and Acquisitions
 - 15.7.5 Certifications
- 16 Global Ankylosing Spondylitis Treatment Market- Drug Distribution Model (Additional Insight)
 - 16.1 Overview
 - 16.2 Potential Distributors

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.3 Key Parameters for Distribution Partner Assessment
- 17 Payment Methods (Additional Insight)
 - 17.1 Government Funded
 - 17.2 Private Insurance
 - 17.3 Out-of-Pocket

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Ankylosing Spondylitis Treatment Market Report and Forecast 2023-2031

Market Report | 2023-04-11 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-13"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com